Bausch Health to Provide Scholarships to 10 Students Living with GI
Diseases
LAVAL, Quebec, February 10, 2025 - Bausch Health Companies Inc.
(NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix
Pharmaceuticals ("Salix"), today announced the opening of the 2025 Salix
Gastrointestinal Health Scholars Program application period. The program will
award 10 exceptional students living with GI disease a scholarship of up to
$10,000 as they work to pursue their higher education goals.
"For the sixth consecutive year, Bausch Health is honored to offer The Salix
Gastrointestinal Health Scholarship to financially support students who are
driven to persevere through their GI diseases and disorders while still
exceling in their academic goals. Through this scholarship program, Salix is
able to uphold our commitment to support GI patients and make a difference in
the lives of all communities we serve," said Aimee Lenar, Executive Vice
President, US Pharma, Bausch Health.
Students can apply for this scholarship by completing the online application,
submitting letters of reference, and writing an essay on the impact having a
diagnosed GI condition has had on their life and the role that a health care
provider played in helping to manage their condition. Scholarships are offered
to school applicants or current attendees of a two- or four-year college,
university, or an advanced (post-high school) vocational or technical school
for the 2025 - 2026 academic year and are available in the following
categories:
-
Undergraduate Scholar Awards for students pursuing
undergraduate degrees.
-
Graduate Scholar Awards for students pursuing graduate
degrees.
-
Working and/or Single Parents Scholar Award for students
who are working parents and/or single parents pursuing undergraduate,
vocational/technical, or graduate degrees.
The application period for the Salix Gastrointestinal Health Scholars Program
will close on May 5, 2025, and scholarship recipients will be notified in the
summer of 2025. To learn more about the scholarship, including eligibility
criteria, terms and conditions, please visit
www.salix.com/scholarship.
About Bausch Health
Bausch Health Companies Inc.
(NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching
lives through our relentless drive to deliver better health outcomes. We
develop, manufacture and market a range of products primarily in
gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics,
international pharmaceuticals and eye health, through our controlling interest
in Bausch + Lomb Corporation. Our ambition is to be a globally integrated
healthcare company, trusted and valued by patients, HCPs, employees and
investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the
largest specialty pharmaceutical businesses in the world and has licensed,
developed and marketed innovative products for the treatment of
gastrointestinal diseases for more than 30 years. For more information about
Salix, visit
www.Salix.com and connect
with us on Twitter and
LinkedIn. For more
information about Bausch Health, visit
www.bauschhealth.com and
connect with us on
LinkedIn
©2025 Salix Pharmaceuticals or its affiliates.
